Pradaxa Shines On Strength Of Results, But Panelists Wary Of Future Trials With Similar Design

Boehinger Ingelheim's dabigatran eked out a unanimous endorsement from FDA's Cardio-Renal Advisory Committee, but the panel had concerns about the potential for bias from the open-label trial design.